Summary of MetaVia Inc. Conference Call Company Overview - **Company Name**: MetaVia Inc. - **Ticker Symbol**: MTVA - **Industry**: Clinical stage biotech focused on cardiometabolic diseases, specifically obesity and MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [1][2] Core Points and Arguments Obesity Market Insights - Over 650 million adults globally are clinically obese, with the current obesity treatment market valued at approximately $10 billion, projected to grow to between $80 billion and $130 billion [3] - The MASH market is emerging, with analysts forecasting annual revenues between $20 billion and $35 billion [4] Product Development - **DA-1726**: An obesity drug currently in Phase I trials, showing promising early results with a 9.1% weight loss and 3.8 inches reduction in waist circumference over 8 weeks [9] - **Vanoglipol (DA-1241)**: A small molecule treatment for MASH, currently in Phase IIa trials, showing significant hepatic effects and well-tolerated in trials [12][25] Competitive Landscape - The obesity treatment space is highly competitive, with major players like Novo Nordisk and Madrigal Pharmaceuticals. Combination therapies are expected to dominate the market [4][27] - DA-1726 is positioned as a potential best-in-class drug, with a unique 3:1 ratio of GLP-1 to glucagon, aiming to achieve superior weight loss and glycemic control compared to competitors [16][20] Clinical Trial Updates - A new Phase I trial for DA-1726 is being initiated to explore higher dosages (up to 64 mg) to enhance efficacy and safety [10][11] - The company is actively seeking partnerships for both DA-1726 and Vanoglipol to enhance development and market entry [12][32] Financial Position - As of September 30, the company reported cash reserves of $14.3 million, with an additional $9 million raised in January [25] - The financial strategy includes maintaining a lean operational structure by leveraging partnerships with research centers in South Korea [13][14] Additional Important Information - The CEO emphasized the importance of conservative reporting of adverse events, noting that moderate vomiting was reported in 83.3% of participants, but this was counted conservatively [21][22] - The company is optimistic about the potential of both drugs and is preparing for data releases at major medical conferences throughout the year [12][26] Conclusion MetaVia Inc. is positioned in a rapidly growing market with promising drug candidates targeting obesity and MASH. The company is focused on advancing its clinical trials while maintaining a strong financial position and seeking strategic partnerships to enhance its market presence.

Core Insights - MetaVia Inc. has developed a robust global patent portfolio for its lead asset DA-1726, which is a dual agonist for treating obesity and metabolic disorders, with protection extending to 2041 [1] - The company has 39 granted and pending patents in the U.S. and internationally, covering the unique peptide structure and therapeutic use of DA-1726 [1] - Recent clinical data indicate that DA-1726 at a 48 mg dose resulted in approximately 9% weight loss, significant waist size reduction, and improvements in blood sugar levels, all with a favorable safety profile [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is developing DA-1726 for obesity treatment and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] - DA-1726 is designed to be administered once weekly subcutaneously and functions as a dual agonist of GLP-1 and glucagon receptors [1] Product Development - DA-1726 has shown best-in-class potential in pre-clinical studies, outperforming semaglutide in weight loss while allowing for greater food intake [1] - The Phase 1 multiple ascending dose trial demonstrated significant potential for weight loss, glucose control, and waist circumference reduction [1] - Planned 16-week titration studies to 48 mg and 64 mg are expected to yield results in Q4 2026, reflecting confidence in the therapy's tolerability [1]

Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **CEO**: Brett Monia - **Conference Date**: January 13, 2026 Key Industry Insights - Ionis has transitioned from an R&D organization to a fully integrated commercial biotechnology company, achieving its first two independent commercial launches in 2025: **Tringulza** and **Donzera** [4][5] - The company has a robust pipeline with **11 medicines in phase 3 development**, indicating a strong future for product approvals and revenue growth [6] Core Products and Launches - **Tringulza**: Approved for familial chylomicronemia syndrome (FCS), generating **$105 million** in net U.S. product sales in 2025 [13] - **Donzera**: Approved for hereditary angioedema (HAE) prophylaxis, launched in September 2025, with positive early prescription trends [8][9] - **Olezarsen**: Positioned as a new standard of care for severe hypertriglyceridemia (SHTG), with a peak revenue potential now upgraded to **over $2 billion** [17][35] Clinical Achievements - Six positive phase 3 data readouts leading to four approved medicines: Tringulza, Donzera, Wainua, and Qalsody [6] - Olezarsen demonstrated a **72% reduction** in fasting triglycerides and an **85% reduction** in acute pancreatitis event rates at 12 months [15][16] - Zolexarsen for Alexander disease shows unprecedented disease-modifying impact, with plans for NDA submission and launch in the second half of 2026 [21][24] Financial Projections - Anticipated **$4 billion** in potential annual peak product revenue from wholly owned pipeline and **$2 billion** from partner medicines, totaling **over $6 billion** at peak [26] - Expected to achieve cash flow break-even by **2028** with sustained positive cash flow thereafter [26] Market Strategy and Launch Preparations - The launch strategy for Olezarsen in SHTG is based on strong physician enthusiasm and a high unmet need, with a field team of **200 individuals** already hired and trained [33][31] - Pricing strategy for Olezarsen is projected between **$10,000 to $20,000** in the U.S., with ongoing engagement with payers to ensure access [37][38] Risks and Challenges - New product launches inherently carry uncertainty, but the demand for Olezarsen is expected to be strong due to the inadequacy of current treatments for SHTG [36] - The company is preparing for potential challenges in achieving broad access and acceptance among healthcare providers [37] Future Outlook - Ionis is well-positioned for continued growth with a steady cadence of new medicines expected to reach the market, including Olezarsen and Zolexarsen in 2026 [24][25] - The company aims to leverage its strong pipeline and market presence to drive revenue growth and enhance shareholder value [28]

Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [2] - The company is developing two key products: DA-1726 for obesity and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [2] Product Development - DA-1726 is a novel oxyntomodulin (OXM) analogue acting as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing best-in-class potential for weight loss, glucose control, and waist reduction in Phase 1 trials [2] - Vanoglipel is a G-protein-coupled receptor 119 (GPR119) agonist that enhances the release of gut peptides GLP-1, GIP, and PYY, demonstrating positive effects on liver inflammation, lipid metabolism, and glucose control in pre-clinical studies and Phase 2a clinical studies [2] Conference Participation - MetaVia will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference from January 8-10, 2026, in Park City, Utah, with members from its business development and clinical teams attending [1]

Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing two key drug candidates: DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] Company Overview - MetaVia is developing DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [4] - DA-1726 demonstrated best-in-class potential in a Phase 1 multiple ascending dose trial, indicating effectiveness in weight loss, glucose control, and waist reduction [4] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, and glucose metabolism in pre-clinical studies [4] - In a Phase 2a clinical study, DA-1241 exhibited direct hepatic action alongside glucose-lowering effects [4] Upcoming Events - MetaVia will participate in several upcoming conferences, including: - Wells Fargo Healthcare Conference from September 3-5, where CEO Hyung Heon Kim will attend [7] - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, featuring a fireside chat and an on-demand presentation available from September 5 [7] - Obesity Science & Innovation 2025 Congress on September 16-17, where Mr. Kim will present an overview focusing on DA-1726 [7] - Fierce Biotech Week from October 7-9, with Mr. Kim's attendance [7]

Core Insights - MetaVia Inc. reported promising results from its Phase 1 clinical trial of DA-1726, indicating a dose-dependent response in body weight reduction, with significant differences in BMI and body weight compared to placebo [1][2][4] - DA-1726 demonstrated a maximum weight loss of -6.3% and a mean weight loss of -4.3% at the 32 mg dose, alongside notable reductions in fasting glucose and waist circumference [3][4] - The drug showed a favorable safety profile, with no significant cardiovascular effects observed, and a slight decrease in heart rate across most treatment groups [4][7] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, particularly obesity [10] - The company is advancing DA-1726, a dual agonist targeting GLP-1 and glucagon receptors, which aims to improve weight loss outcomes compared to existing therapies [9][10] Clinical Trial Details - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving 36 subjects, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726 [6] - The trial's primary endpoint was to evaluate the safety and tolerability of DA-1726, while secondary endpoints included pharmacokinetic assessments and exploratory metabolic parameters [6] Future Directions - MetaVia plans to conduct a Phase 1 Part 3 study to evaluate DA-1726 in patients who discontinued other GLP-1 agonists, aiming to demonstrate improved tolerability and weight loss outcomes [5] - Additional cohorts will be added to determine the maximum tolerated dose of DA-1726, with expectations of enhanced efficacy at higher doses [5]